BioCentury
ARTICLE | Clinical News

THV01-1: Phase I/II start

December 10, 2012 8:00 AM UTC

By year end, Theravectys will begin the double-blind, placebo-controlled, European Phase I/II THV01 trial to evaluate 3 dose levels of intramuscular THV01-1 followed by THV01-2 given 8 weeks apart in...